| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yingchun Xu, Deng Chen, Ling Li. Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials. Frontiers in neurology. vol 15. 2024-04-09. PMID:38590719. |
optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials. |
2024-04-09 |
2024-04-11 |
Not clear |
| Yingchun Xu, Deng Chen, Ling Li. Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials. Frontiers in neurology. vol 15. 2024-04-09. PMID:38590719. |
several clinical trials have suggested that fenfluramine (ffa) is effective for the treatment of epilepsy in dravet syndrome (ds) and lennox-gastaut syndrome (lgs). |
2024-04-09 |
2024-04-11 |
Not clear |
| Kinga Borowicz-Reutt, Julia Czernia, Marlena Krawczy. Genetic Background of Epilepsy and Antiepileptic Treatments. International journal of molecular sciences. vol 24. issue 22. 2023-11-25. PMID:38003469. |
as a result, some medications that are not regular antiseizure drugs (e.g., soticlestat, fenfluramine, or ganaxolone) have been introduced to the treatment of drug-resistant seizures in dravet, lennox-gastaut, maternally inherited chromosome 15q11.2-q13.1 duplication (dup 15q) syndromes, and protocadherin 19 (pcdh 19)-clusterig epilepsy. |
2023-11-25 |
2023-11-28 |
Not clear |
| Kinga Borowicz-Reutt, Julia Czernia, Marlena Krawczy. Genetic Background of Epilepsy and Antiepileptic Treatments. International journal of molecular sciences. vol 24. issue 22. 2023-11-25. PMID:38003469. |
and although the effects of soticlestat, fenfluramine, and ganaxolone are described as promising, they do not significantly affect the course of the mentioned epilepsy syndromes. |
2023-11-25 |
2023-11-28 |
Not clear |
| Jo Sourbron, Lieven Laga. Fenfluramine: a plethora of mechanisms? Frontiers in pharmacology. vol 14. 2023-05-30. PMID:37251322. |
the antiseizure medication (asm) fenfluramine is an effective treatment for reducing seizure frequency, ameliorating comorbidities, and potentially reducing risk of sudden unexpected death in epilepsy (sudep) in patients with dravet syndrome and lennox-gastaut syndrome, among other rare epilepsies. |
2023-05-30 |
2023-08-14 |
Not clear |
| Pavel Klein, Gregory L Krauss, Bernhard J Steinhoff, Orrin Devinsky, Michael R Sperlin. Failure to use new breakthrough treatments for epilepsy. Epilepsia. 2023-03-01. PMID:36855241. |
in 2020 two new asms were launched in the us, cenobamate for focal epilepsy in adults and fenfluramine for dravet syndrome (ds). |
2023-03-01 |
2023-08-14 |
Not clear |
| Payam Tabaee Damavandi, Natalia Fabin, Riccardo Giossi, Sara Matricardi, Cinzia Del Giovane, Pasquale Striano, Stefano Meletti, Francesco Brigo, Eugen Trinka, Simona Lattanz. Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis. Neurology and therapy. 2023-02-28. PMID:36853503. |
efficacy and safety of fenfluramine in epilepsy: a systematic review and meta-analysis. |
2023-02-28 |
2023-08-14 |
Not clear |
| Gianluca Dini, Eleonora Tulli, Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano, Alberto Verrott. Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine. Frontiers in pharmacology. vol 13. 2023-01-23. PMID:36686669. |
corrigendum: improving therapy of pharmacoresistant epilepsies: the role of fenfluramine. |
2023-01-23 |
2023-08-14 |
Not clear |
| Debopam Samant. Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy. Children (Basel, Switzerland). vol 9. issue 8. 2022-08-26. PMID:36010049. |
fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. |
2022-08-26 |
2023-08-14 |
Not clear |
| Gianluca Dini, Eleonora Tulli, Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano, Alberto Verrott. Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine. Frontiers in pharmacology. vol 13. 2022-06-07. PMID:35668937. |
this review aims to provide a comprehensive analysis of the literature, including ongoing trials, regarding the efficacy and safety of fenfluramine as adjunctive treatment of pharmacoresistant epilepsies. |
2022-06-07 |
2023-08-14 |
Not clear |
| Gianluca Dini, Eleonora Tulli, Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano, Alberto Verrott. Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine. Frontiers in pharmacology. vol 13. 2022-06-07. PMID:35668937. |
improving therapy of pharmacoresistant epilepsies: the role of fenfluramine. |
2022-06-07 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Leanne Lehmann, Kevin M Knox, Melissa Barker-Halisk. Can Old Animals Reveal New Targets? The Aging and Degenerating Brain as a New Precision Medicine Opportunity for Epilepsy. Frontiers in neurology. vol 13. 2022-05-16. PMID:35572927. |
for example, cannabidiol and fenfluramine demonstrated clear efficacy in syndrome-specific pediatric models that led to a paradigm shift in the perceived value of pediatric models for asm discovery practice; aged rodents with seizures or rodents with aging-related neuropathology represent an untapped resource that could similarly change epilepsy drug discovery. |
2022-05-16 |
2023-08-13 |
Not clear |
| Jo Sourbron, Lieven Laga. Serotonin receptors in epilepsy: novel treatment targets? Epilepsia open. 2022-01-25. PMID:35075810. |
there are divergent data demonstrating that modulation of distinct serotonin (5-hydroxytryptamine, 5-ht) receptors subtypes could be beneficial in the treatment of epilepsy and its comorbidities, whereas only few asm, such as fenfluramine (fa), act via 5-ht. |
2022-01-25 |
2023-08-13 |
human |
| An-Sofie Schoonjans, Laurence Roosens, Wendy Dewals, Bernard P Paelinck, Berten Ceuleman. Therapeutic drug monitoring of fenfluramine in clinical practice: Pharmacokinetic variability and impact of concomitant antiseizure medications. Epilepsia. 2022-01-15. PMID:35032026. |
this study was undertaken to determine the plasma concentration and pharmacokinetic variability of fenfluramine (ffa) and its main active metabolite norfenfluramine (norffa) in relation to the prevalence of adverse effects in patients with refractory epilepsy treated with ffa. |
2022-01-15 |
2023-08-13 |
Not clear |
| Reem Odi, Roberto William Invernizzi, Tamar Gallily, Meir Bialer, Emilio Perucc. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. Pharmacology & therapeutics. vol 226. 2021-11-09. PMID:33895186. |
fenfluramine repurposing from weight loss to epilepsy: what we do and do not know. |
2021-11-09 |
2023-08-13 |
Not clear |
| Kimford J Meado. Seizure Reduction with Fluoxetine in Dravet Syndrome. Epilepsy & behavior case reports. vol 2. 2021-10-21. PMID:24955329. |
fenfluramine may produce this effect by increasing serotonin brain levels, and ssris have been found to possess antiepileptic properties in animal models of epilepsy. |
2021-10-21 |
2023-08-13 |
Not clear |
| Kimford J Meado. Seizure Reduction with Fluoxetine in Dravet Syndrome. Epilepsy & behavior case reports. vol 2. 2021-10-21. PMID:24955329. |
given the known cardiac risks of fenfluramine, consideration of randomized clinical trials with ssris should be considered in dravet syndrome and other epilepsies. |
2021-10-21 |
2023-08-13 |
Not clear |
| Maria Gogou, J Helen Cros. Fenfluramine as antiseizure medication for epilepsy. Developmental medicine and child neurology. vol 63. issue 8. 2021-10-11. PMID:33565102. |
fenfluramine as antiseizure medication for epilepsy. |
2021-10-11 |
2023-08-13 |
zebrafish |
| Ernesto Gonzalez-Giraldo, Joseph E Sulliva. Advances in the Treatment of Drug-Resistant Pediatric Epilepsy. Seminars in neurology. vol 40. issue 2. 2021-07-26. PMID:32185791. |
recent publications have shown the efficacy of new pharmaceutical options such as fenfluramine and cannabidiol, some of which have been tested specifically in patients with childhood-onset epilepsy syndromes such as dravet's syndrome and lennox-gastaut's syndrome. |
2021-07-26 |
2023-08-13 |
Not clear |
| J Sullivan, R Simmon. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies. Drugs of today (Barcelona, Spain : 1998). vol 57. issue 7. 2021-07-19. PMID:34268532. |
fenfluramine for treatment-resistant epilepsy in dravet syndrome and other genetically mediated epilepsies. |
2021-07-19 |
2023-08-13 |
Not clear |